InMed (INM) news

InMed Incorporated - Three phase 3 studies initiated; fourth to begin in first half of 2027

China National Building Material - CNBM expects unaudited loss of RMB 760 mln for nine months ended Sept 30, 2026

China National Building Material (CNBM), based in Beijing, has reported an unaudited loss of RMB 760 million for the nine months ended Sept 30, 2026. This update follows earlier projections of increased first-quarter losses, which were attributed to declining product prices, weaker performance from…

Inmed: Mentari deal expected to close in 2H 2026

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced that the acquisition of Mentari is expected to close in the second half of 2026, according to recent disclosures. The deal, which is still in the final stages of negotiation and regulatory review, is anticipated to expand InMed’s pipeline of…

Inmed: $290M placement of Mentari to fund company operations through 2028

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced a $290 million private placement of its subsidiary, Mentari, to fund company operations through 2028. The capital raise is intended to support the continued development of InMed’s pipeline of proprietary small molecule drug candidates,…

Inmed: combined co. to have equity value of about $421.4M

InMed Pharmaceuticals Inc. is projected to have an equity value of approximately $421.4 million as of May 2026, reflecting the company’s transformation into a revenue-generating entity following its 2021 acquisition of BayMedica Inc. . The acquisition, which was structured as a share-based…